People in the study will receive Ketosteril together with their usual nutritional care, and their course will be followed over time. The study will compare how long the lower-frequency dialysis period lasts and will also look at general health, hospital stays, survival, eating and nutrition, and overall quality of life. The study is exploratory, which means it is intended to learn more about whether this approach may be useful.

During the study, health checks and routine follow-up will be done at regular visits. Information about dialysis sessions, diet, and general well-being will be collected to understand how the treatment works in everyday care.

The purpose of the study is to see how this nutrition given during dialysis affects the way muscles build new proteins and to understand how it affects blood pressure and heart function during the dialysis treatment. The study will compare periods when patients receive the nutrition solution during dialysis with periods when they do not receive it. During the study, researchers will measure how quickly the muscles make new proteins and will track the levels of amino acids in the blood and in the fluid removed during dialysis. They will also monitor blood pressure and how well the heart is pumping blood throughout the treatment sessions.

Participants will undergo dialysis sessions three times per week as they normally would, but during some weeks they will receive the additional nutrition through their dialysis access point. The study will involve taking blood samples and measuring various aspects of muscle and heart function. The research will last for several weeks for each participant, allowing researchers to compare the effects of receiving nutrition during dialysis versus not receiving it. This information will help doctors understand whether giving nutrition during dialysis can help hemodialysis patients maintain or improve their muscle health.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about six months, during which time the participants will continue their regular hemodialysis treatments while taking the study medication or placebo. The main focus will be on changes in the heart’s structure and function, particularly the Left Ventricular Mass, which is a measure of the heart’s size and health.

Throughout the study, various health markers will be monitored, including blood sugar levels, hormones, and heart function indicators. The goal is to see if dapagliflozin can improve heart health and overall quality of life for patients on hemodialysis. The study will provide valuable information on whether this medication can be beneficial for people with kidney and heart conditions who are undergoing hemodialysis.

The study will compare two different approaches during dialysis sessions: one using Medialipide, which is a special fat-based solution containing medium-chain triglycerides and soya oil, and another using standard sodium chloride solution (salt water). Each dialysis session in the study will last for 4 hours, during which these solutions will be given through an intravenous line.

During the treatment, researchers will measure how effectively the dialysis removes various harmful substances from the blood. They will also monitor the safety of using Medialipide by checking for side effects such as nausea, vomiting, headaches, and by measuring blood levels of fats and liver function. Blood samples will be taken at different times during the dialysis session to measure the levels of various substances.

Participants in the study will receive one of three different daily doses of rivaroxaban: 5 mg, 10 mg, or 15 mg. The study will monitor how the body processes the medication and its effects on the blood, which is referred to as pharmacokinetics and pharmacodynamics. The study will also observe any bleeding events that may occur during the trial period, as bleeding is a potential side effect of anticoagulant medications.

The purpose of this study is to identify the dose of rivaroxaban that provides the best balance of safety and effectiveness for patients with end-stage renal disease on chronic hemodialysis. The trial is expected to run until April 2025, with recruitment starting in April 2024. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the medication’s effects.

Participants in the study will receive tacrolimus orally, which means they will take it by mouth. The study will last for a period of 14 days. During this time, researchers will monitor changes in the participants’ glycemic profile, which refers to the levels of sugar in the blood. The goal is to determine if there is a significant change in blood sugar levels from the start of the treatment to the end of the 14-day period.

This study is important for understanding how tacrolimus might affect blood sugar levels in patients who are on dialysis and preparing for a kidney transplant. The findings could help improve the management of these patients’ conditions and provide insights into the safe use of tacrolimus in this specific group of patients.

Participants in the study will receive cefazolin as part of their regular care. The study will monitor how the medication is processed in the body, specifically looking at how long the drug stays in the bloodstream at effective levels. This will help determine the best way to use cefazolin in treating infections in these patients. The study will also observe any side effects that may occur within six weeks after the last dose of the medication.

Throughout the study, researchers will assess the early and late effectiveness of cefazolin in treating infections. Early effectiveness will be checked one week after starting treatment, while late effectiveness will be evaluated six weeks after starting treatment. The study aims to ensure that the medication is working properly and to identify any factors that might affect how the drug is processed in the body. This information will be valuable in improving treatment for patients with infections who are on chronic hemodialysis.

The purpose of this study is to understand how well Warfarin, a medication that helps prevent blood clots, works in patients who are on dialysis and have atrial fibrillation. The study will compare patients taking Warfarin with those who are not receiving any treatment to see if there are differences in the occurrence of events like strokes or transient ischemic attacks, which are often referred to as mini-strokes. The study will also look at the risk of major bleeding, which can occur in different parts of the body, such as the brain or stomach.

Participants in the study will be randomly assigned to either receive Warfarin or no treatment. The study will be conducted over a period of time, and researchers will monitor the health of the participants to gather information on the safety and effectiveness of the medication. This information will help doctors understand the best ways to treat patients with atrial fibrillation who are also undergoing dialysis.